Methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia is often fatal. To determine predictors of risk for death, we conducted a retrospective cohort study. We examined 699 episodes of MRSA bacteremia involving 603 patients admitted to an academic medical center in New York City during 2002–2007. Data came from chart reviews, hospital databases, and recultured frozen MRSA specimens. Among the 699 episodes, 55 were caused by vancomycin–intermediate resistant *S. aureus* strains, 55 by heteroresistant vancomycin-intermediate *S. aureus* strains, and 589 by non–vancomycin-resistant strains; 190 (31.5%) patients died. We used regression risk analysis to quantify the association between clinical correlates and death. We found that older age, residence in a nursing home, severe bacteremia, and organ impairment were independently associated with increased risk for death; consultation with an infectious disease specialist was associated with lower risk for death; and MRSA strain types were not associated with risk for death.

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a worldwide concern; it colonizes and infects patients in the hospital and in the community (1). For the past 50 years in the United States, the standard therapy has been vancomycin. Recent vancomycin treatment failures have raised questions regarding optimal treatment (2). Although new antimicrobial drugs (e.g., linezolid, daptomycin, tigecycline) have been developed, none has been consistently superior to vancomycin for the treatment of MRSA (3,4), and MRSA resistance rapidly develops for many new drugs (5,6). Some studies have suggested MIC creep (increasing vancomycin MICs against MRSA over time), but others have not (7,8). In 2006, the upper limit of vancomycin susceptibility for *S. aureus* was redefined, lowered from 4 μg/mL to 2 μg/mL, first by the Clinical and Laboratory Standards Institute and soon thereafter by the US Food and Drug Administration and the European Committee on Antimicrobial Susceptibility (9).

Vancomycin treatment failures for MRSA occur even when MICs are within the range considered susceptible, especially 1–2 μg/mL (10–13). Among high-risk bacteremic patients, Sakoulas et al. documented treatment failure rates of 44% when vancomycin MICs were <0.5 μg/mL and of 90% when vancomycin MICs were 1–2 μg/mL (p = 0.01) (10). Hidayat et al. found that mortality rates were higher for patients infected with strains with higher vancomycin MICs (11).

Some apparently susceptible strains of MRSA might actually be heteroresistant vancomycin-intermediate *S. aureus* (hVISA) strains. That is, although the hVISA isolates seem to be susceptible to vancomycin according to conventional testing, the isolates contain subpopulations of colonies resistant to vancomycin. Testing for hVISA has not been standardized and is not routinely undertaken. hVISA strains are more common in strains with higher vancomycin MICs (14,15). hVISA might contribute to worse clinical outcomes, but this possibility has not been convincingly confirmed by large studies.

To determine predictors of risk for death among patients with MRSA bacteremia, we conducted a retrospective study that compared demographic and clinical characteristics of adult patients with MRSA bacteremia. MRSA strains from...
these patients were vancomycin susceptible, VISA, and hVISA. We analyzed a 5-year trend of vancomycin MICs among adult patients with MRSA bacteremia. We also analyzed the associations between host factors, organism factors, and death versus survival, and quantified the marginal contribution of key factors to risk for death.

Methods

Our retrospective study was conducted in New York, New York, USA, at Mount Sinai Medical Center, a 1,171-bed tertiary-care academic center that serves a diverse ethnic and medical population. We studied 699 episodes of blood infection from 603 patients who had had MRSA bacteremia during 2002–2007. This study was approved by the institutional review board of the Mount Sinai School of Medicine.

Laboratory Specimens

At Mount Sinai Medical Center, MRSA organisms identified from blood culture are routinely stored frozen at −70°C. We retrieved frozen blood culture isolates (previously not thawed or subcultured) for all adult patients hospitalized with MRSA bacteremia from January 2002 through May 2007. We excluded episodes of polymicrobial bacteremia if MRSA was isolated in a single blood culture bottle or if the patient received inappropriate empirical treatment for the co-pathogen. We included in our analysis the first organism isolated from blood culture during any episode of MRSA bacteremia.

A computerized data system identified 748 eligible isolates, among which we were able to retrieve 699 (93.4%). These isolates had originally been tested for drug susceptibility by use of an automated instrument, the Microscan (Siemens Healthcare, Sacramento, CA, USA); for all isolates, the vancomycin MICs were ≤2 μg/mL; during 2002–2007, we used the Positive Breakpoint Combo 20 (Siemens Healthcare), which might not accurately detect VISA isolates (16). We sent some isolates—8 (15%) VISA strains, 88 (15%) non-VISA strains, and 10 VISA control strains (from the Network on Antimicrobial Resistance in Staphylococcus aureus, www.narsa.net)—to an outside laboratory for blinded testing by using the Vitek 2 (bioMérieux, Durham, NC, USA) with the AST-GP-67 card, and we sent 8 (15%) hVISA isolates to an outside laboratory for retesting by using time-killing profiles. No discrepancies were noted.

Retesting of isolates was performed with no access (blinded) to clinical data. Mueller-Hinton agar plates (study and control strains) were inoculated with 0.5 McFarland inoculum (10⁶ CFU/mL), and antimicrobial drug susceptibility to vancomycin was assessed by using Etest (AB Biodisk, Solna, Sweden), which has excellent sensitivity and specificity for this purpose (17). Isolates for which vancomycin MICs were ≥1 μg/mL (95.1%) were tested for the presence of hVISA by using vancomycin and teicoplanin Etest strips (the Etest macromethod). In brief, study and control inocula equivalent to 2.0 McFarland turbidity standard were plated on brain–heart infusion and Mueller-Hinton agars and incubated at 35°C–37°C for 24 and 48 hours, respectively. Isolates were interpreted as being hVISA strains when vancomycin and teicoplanin MICs were ≥8 μg/mL or teicoplanin-only MIC was ≥12 μg/mL (16). Quality control testing was performed weekly by using American Type Culture Collection (Manassas, VA, USA) organisms 29213, 29212, 700698 (hVISA), and 700699 (VISA) per Clinical and Laboratory Standards Institute guidelines (9). Actual Etest values were used for MIC₉₀ (the value below which 50% of MIC values for MRSA isolates tested fell), MIC₅₀ (the value below which 90% of MICs fell), and geometric mean MIC calculations.

Chart Review

We abstracted electronic and paper charts for each of the 603 patients corresponding to the 699 isolates; 65 of these patients were hospitalized ≥2 times for MRSA bacteremia. Chart abstraction was performed by 2 independent reviewers with no access (blinded) to laboratory data. Each reviewer separately examined 10% of charts; the κ statistic for coding of exemplar key variables was 0.87, indicating excellent agreement (18). Each new hospital admission was categorized as a new episode of bacteremia; the first positive blood culture was used as the index infection. We abstracted patient information regarding demographics, concurrent illnesses, patient’s residence before hospitalization (facility vs. community), bacteremia severity, and previous health care exposures.

Definitions

We categorized each MRSA infection into 1 of 3 groups according to Etest result for vancomycin MICs as follows: VISA (MIC 4–12 μg/mL), hVISA, or non-VISA/hVISA MRSA (MIC ≤2 μg/mL). We also assessed MIC₅₀ and MIC₉₀ for vancomycin.

We defined the number of days to clearance of bacteremia as the date of first positive MRSA culture subtracted from the date of first negative culture for all patients for whom this information was available. Episodes of bacteremia ended on the date of death or on the date of the first negative blood culture that was not followed by a positive culture within 7 days. We did not study subsequent episodes during the same hospitalization. Vancomycin trough levels were measured after 3 doses of vancomycin; if multiple levels were measured, the modal level was used and classified as either ≥15 μg/mL or <15 μg/mL. We defined prior vancomycin exposure as receipt of ≥3 doses of vancomycin at least 7 days and ≤12 months
before MRSA bacteremia. Empirically prescribed therapy was defined as appropriate if MRSA were susceptible to the antimicrobial drug used (according to in vitro susceptibility testing) and if therapy was started within 48 hours of the blood culture result. History of MRSA infection was defined as hospitalization with MRSA during the prior 12 months. We defined an episode as community associated if the patient was bacteremic within 48 hours of hospitalization and lacked health care–associated risk factors such as dialysis, nursing home residence, or history of MRSA infection. We divided health care–associated MRSA cases into community onset or hospital onset. Cases were health care–associated community onset if the patient had such risk factors and was found to be bacteremic within 48 hours of hospital admission; cases were of health care–associated hospital onset if the bacteremia occurred after 48 hours of hospitalization, consistent with the schema of Klevens et al. (19).

We defined renal insufficiency as serum creatinine level ≥2 mg/dL or glomerular filtration rate <50 mL/min/1.73 m² according to the Cockcroft-Gault equation. The source of the bacteremia was determined by a combination of positive MRSA culture growth from a site other than blood, radiologic evidence, or an attending physician’s statement in the medical record. We used the Duke criteria to define endocarditis (20). Severity of bacteremia at onset of infection was determined by use of vasopressors, elevation of serum creatinine levels from baseline (renal insufficiency), and admission to an intensive care unit after positive MRSA blood culture result. The major patient outcome measure was 90-day all-cause mortality rate. Mortality rate was determined by calculating deaths from the date of positive MRSA blood culture result up to 90 days while hospitalized, divided by the number of patients in the study (n = 603). Data regarding death after hospital discharge were not available for analysis. MRSA-attributable deaths were not included because of the difficulty in assessing exact cause of death.

Statistical Analysis

We used SAS version 9.1 (SAS Institute, Cary, NC, USA) for statistical analyses (21). We used standard methods to describe univariate data and to calculate t-tests, and we used χ² for bivariate associations. We used generalized linear models (SAS Proc GLM) to assess associations between the 3 groups of MRSA infection and quantitative variables. We conducted multivariable analyses by using logistic regression (SAS Proc Logistic). We developed models for 3 variables: infection with VISA, infection with hVISA, and death. Model building was guided first by conceptual models of likely effect and informed by our bivariate analysis results. We assessed correlation coefficients between pairs of potential predictor variables by using appropriate parametric or nonparametric methods and included only 1 of any pair of variables with an r² of >0.25 in any model. Guided by the rule for stability of estimates established by Peduzzi et al., we limited the total number of predictor variables in any model (22). The significance of the models (Tables 1, 2) are demonstrated by likelihood ratios, Wald <0.0001. When choosing between similar or comparable models, we selected the model associated with the smallest Akaike information criterion (<582); for example, in our analysis of predictors of risk for death, we rejected variables indicating HIV, malignancy, transplant, recent surgery, and presence of a medical device because they increased the Akaike information criterion. The predictive and discriminative performance of our models is shown in Tables 1 and 2. Our model predicting death has a c-score of 0.872; among 99,198 pairs, 87.1% were concordant, 12.7% were discordant, and 0.2% had the same scores. Although we also present the more familiar adjusted odds ratios, our primary measures of impact are adjusted risk measures (adjusted risk ratio and adjusted risk difference), which we derived from regression risk analysis, an enhancement over the usual presentation of logistic regression (23).

Results

Bacteria Characteristics

Each year during 2002–2006, the annual number of hospital admissions in this study were 117, 77, 147, 121, and 161, respectively; through May 31, 2007, another 76 patients were hospitalized (equivalent to 184 annual hospitalizations). The original testing of strains by Microscan did not detect VISA; repeat testing using the Vitek 2 detected 2 (25%) of 8 study strains and 2 (20%) of 10 control strains. The rate at which polymicrobial bacteremia met inclusion criteria was 3% (20 episodes). The Figure demonstrates the proportion of VISA, hVISA, and non–VISA/hVISA MRSA by year and the increase in mean vancomycin MICs during the study period. The vancomycin MICs for most (87%) isolates were 1–2 μg/mL. For VISA, MICs were as high as 12 μg/mL, although for 60%, MICs were 4 μg/mL. For 94% of hVISA strains, vancomycin MICs were 1.5–2.0 μg/mL.

The geometric mean MIC of vancomycin was 1.7 μg/mL; modal MIC = 2 μg/mL. In 2002, the MIC₉₀ of vancomycin was 1.5 μg/mL; by 2007, it was 2 μg/mL. The MIC₉₀ was constant during the study period; vancomycin MIC₉₀ was 4 μg/mL in 2002 and 2004–2007.

Patient Characteristics

Key patient characteristics are shown in Table 3. Recent medical care seemed to be associated with type of strain. Nearly 40% of infections were health care–community
associated, almost all the rest were hospital associated. Average length of stay for patients with all infection types was 32.9 days. Many cases of MRSA bacteremia were in patients with renal insufficiency and/or cardiovascular disease; >40% had recently had a surgical procedure. Many (43%) cases of bacteremia were secondary to central venous catheter infections. The 90-day all-cause mortality rate was 31.5% for the 603 patients; rate was 27.2% when all 699 episodes of bacteremia were considered.

**Treatment and Changes in Treatment Regimens**

Among the 603 patients, 47% had been exposed to vancomycin and 60% of these had had prior MRSA infection. Prior vancomycin exposure was more likely for patients with VISA (62%, 95% CI 47.7%–65.3%) than for patients with hVISA (42%, 95% CI 29.4%–59%) or other MRSA strains (47%, 95% CI 41.3%–49.7%).

Among the 699 episodes of MRSA bacteremia, vancomycin was used to treat 566 (81%) episodes. Initial vancomycin treatment was switched to daptomycin or linezolid for 12% of MRSA (non-VISA, non-hVISA) infections and 15% of VISA infections. For the 699 episodes of bacteremia, mortality rates were 27.2% overall, 16% (95% CI 6.8%–24.8%) when antimicrobial drug treatment was changed, and 26% (95% CI 22.2%–29.8%) when not changed. Our data did not enable us to determine the extent

---

**Table 1. Multivariable analysis of risk factors for VISA and hVISA infections, New York, New York, USA, 2002–2007**

| Risk factor and MRSA strain | Odds ratio | Adjusted risk ratio (95% CI) | Adjusted risk difference (95% CI)† |
|-----------------------------|------------|-----------------------------|----------------------------------|
| Age‡                        |            |                             |                                  |
| VISA                        | 0.93       | 0.82 (0.65 to 1.12)         | −0.020 (−0.080 to 0.007)         |
| hVISA                       | 0.93       | 0.96 (0.73 to 1.35)         | −0.003 (−0.050 to 0.013)         |
| Race/ethnicity              |            |                             |                                  |
| Black                       | 0.90       | 0.76 (0.35 to 1.57)         | −0.02 (−0.07 to 0.04)            |
| Hispanic                    | 0.90       | 1.03 (0.44 to 2.13)         | 0.002 (−0.050 to 0.070)          |
| Asian                       | 0.89       | 0.87 (0.36 to 1.88)         | −0.01 (−0.06 to 0.05)            |
| Asian                       | 0.46       | 0.62 (0.19 to 1.37)         | −0.03 (−0.08 to 0.03)            |
| Concurrent condition        |            |                             |                                  |
| Diabetes                    | 1.42       | 1.44 (0.78 to 2.59)         | 0.03 (−0.02 to 0.08)             |
| HIV                         | 0.69       | 0.87 (0.48 to 1.48)         | −0.01 (−0.05 to 0.03)            |
| Chronic hemodialysis        | 1.25       | 1.23 (0.56 to 2.57)         | 0.02 (−0.04 to 0.09)             |
| HIV                         | 1.32       | 1.05 (0.48 to 2.03)         | 0.004 (−0.040 to 0.060)          |
| Liver cirrhosis             | 2.38       | 3.43 (2.02 to 6.00)         | 0.14 (0.06 to 0.23)              |
| Malignancy                  | 2.55       | 2.11 (1.08 to 3.87)         | 0.080 (0.005 to 0.170)           |
| Other                       |            |                             |                                  |
| Nursing home residence      | 1.62       | 1.83 (0.88 to 3.30)         | 0.060 (−0.009 to 0.130)          |
| hVISA                       | 1.12       | 0.94 (0.36 to 1.80)         | −0.005 (−0.060 to 0.050)         |
| Surgical procedure§         | 0.50       | 0.41 (0.20 to 0.76)         | −0.06 (−0.10 to −0.02)           |
| hVISA                       | 0.79       | 0.62 (0.32 to 1.02)         | −0.040 (−0.080 to 0.002)         |
| Prior receipt of vancomycin | 1.87       | 2.09 (1.25 to 3.67)         | 0.06 (0.02 to 0.10)              |
| hVISA                       | 0.92       | 0.97 (0.56 to 1.65)         | −0.002 (−0.040 to 0.040)         |
| Central venous catheter infection | 0.80   | 0.83 (0.50 to 1.36)         | −0.01 (−0.05 to 0.02)            |
| hVISA                       | 2.09       | 1.81 (1.13 to 3.10)         | 0.050 (0.009 to 0.090)           |

†Adjusted risk difference refers to the absolute difference in risk; for example, an adjusted risk difference of 0.10 signifies a 10% increased risk for hVISA, VISA, given that variable.

‡Measures are adjusted odds ratio for a 10-y difference and adjusted risk difference for effect of age 50–60 y.

§Surgical procedures under general anesthesia within the past 3 months.
Correlates of VISA and hVISA Infections

Multivariable analyses (Table 1) demonstrate associations between key clinical characteristics and VISA or hVISA infections. The adjusted risk difference represents the absolute difference in risk for that given characteristic, all else held equal. Cirrhosis of the liver and central venous catheter infections nearly doubled the risk for hVISA infection. Cirrhosis and active malignancy increased the absolute risk for VISA by 14% and 7%, respectively. History of vancomycin exposure within 1 year increased the risk for VISA by 14% and 7%, and hVISA infections by 15% and 4%, respectively. The absolute increase in risk for death of approximately 50% for those who required vasopressors had an absolute increase in risk for death of 50–60 y.

Discussion

The idealized model for the treatment of patients with infectious diseases incorporates the triad of host, organism, and drug. Organisms and drugs are more easily classified and hence more accessible for systematic study. Our study of the 5-year experience with MRSA infections in adults at a major New York City medical center illustrates why such a dyadic approach might be insufficient. For example, the MIC, which characterizes the major intersection between organism and drug, was overshadowed by a constellation of clinical factors when predicting risk for death. Vancomycin MICs from isolates from most persons who died indicated a 10% increased risk for all-cause deaths given that variable.

A subanalysis of vancomycin MICs for strains infecting patients who died in the hospital found that the mean MIC was 1.7 μg/mL. The current breakpoint for vancomycin susceptibility is 2 μg/mL.

Table 2. Multivariable analysis of risk factors for 90-day all-cause deaths among 603 patients with MRSA bacteremia, New York, New York, USA, 2002–2007*

| Risk factor                          | Odds ratio (95% CI) | Adjusted risk ratio (95% CI) | Adjusted risk difference† (95% CI) |
|-------------------------------------|---------------------|-----------------------------|-----------------------------------|
| Age‡                               | 1.72 (1.29 to 2.30) | 1.34 (1.12 to 1.65)         | 0.04 (0.03 to 0.05)                |
| Race/ethnicity                      |                     |                             |                                   |
| Black                               | 0.71 (0.39 to 1.29) | 0.85 (0.63 to 1.16)         | −0.04 (−0.04 to −0.11)            |
| Hispanic                            | 0.85 (0.45 to 1.58) | 0.93 (0.66 to 1.23)         | −0.02 (−0.10 to 0.06)             |
| Asian                               | 1.83 (0.92 to 3.66) | 1.30 (0.95 to 1.72)         | 0.08 (−0.01 to 0.18)              |
| Concurrent condition                |                     |                             |                                   |
| Diabetes                            | 0.50 (0.31 to 0.83) | 0.73 (0.57 to 0.93)         | −0.08 (−0.14 to −0.02)            |
| Immunosuppressant use               | 0.83 (0.37 to 1.83) | 0.92 (0.63 to 1.30)         | −0.02 (−0.10 to 0.08)             |
| Liver cirrhosis                     | 2.18 (1.16 to 4.12) | 1.40 (1.04 to 1.77)         | 0.10 (0.01 to 0.19)               |
| Renal insufficiency                 | 1.89 (1.18 to 3.01) | 1.33 (1.05 to 1.70)         | 0.08 (0.01 to 0.14)               |
| Other                               |                     |                             |                                   |
| Infectious disease consultation     | 0.43 (0.26 to 0.69) | 0.69 (0.57 to 0.86)         | −0.11 (−0.16 to −0.04)            |
| History of MRSA infection           | 0.77 (0.45 to 1.34) | 0.89 (0.70 to 1.13)         | −0.03 (−0.09 to 0.04)             |
| Nursing home residence              | 3.08 (1.81 to 5.24) | 1.62 (1.31 to 2.06)         | 0.15 (0.08 to 0.23)               |
| Intensive care unit stay            | 1.71 (1.17 to 2.56) | 1.29 (1.11 to 2.15)         | 0.07 (0.03 to 0.20)               |
| Vasopressor use                     | 15.44 (8.58 to 27.76) | 3.67 (2.66 to 4.66)     | 0.48 (0.34 to 0.58)               |
| Inappropriate antimicrobial drug therapy | 1.38 (0.73 to 2.63) | 1.15 (0.89 to 1.46)         | 0.04 (−0.03 to 0.12)              |
| MRSA strain                         |                     |                             |                                   |
| VISA                                | 0.58 (0.24 to 1.38) | 0.78 (0.49 to 1.19)         | −0.06 (−0.15 to 0.05)             |
| hVISA                              | 1.23 (0.54 to 2.82) | 1.10 (0.67 to 1.58)         | 0.03 (−0.09 to 0.16)              |
| Infection source                    |                     |                             |                                   |
| Pneumonia                           | 1.77 (0.85 to 3.64) | 1.28 (0.91 to 1.68)         | 0.07 (−0.02 to 0.17)              |
| Vascular graft infection            | 0.21 (0.03 to 1.70) | 0.460 (0.005 to 0.940)      | −0.15 (−0.29 to −0.02)            |
| Endocarditis                        | 1.49 (0.80 to 2.79) | 1.19 (0.87 to 1.51)         | 0.05 (−0.03 to 0.13)              |

*Results from logistic regression with outcomes and covariates. MRSA, methicillin-resistant Staphylococcus aureus. VISA, vancomycin-intermediate S. aureus strains, hVISA, heteroresistant vancomycin-intermediate S. aureus strains.
†Adjusted risk difference refers to the absolute difference in risk; for example, an adjusted risk difference of 0.10 signifies a 10% increased risk for all-cause deaths given that variable.
‡Measures are adjusted odds ratio for a 10-y difference and adjusted risk difference for effect of age 50–60 y.

To which switching, or not switching, antimicrobial drugs contributed to survival.

Predictors of All-Cause Death

The effect of various clinical characteristics on risk for death within 90 days is summarized in Table 2. For patients with concomitant MRSA bacteremia, older age increased the risk of dying. Cirrhosis or renal insufficiency and having lived in a nursing home before hospitalization or having been admitted to an intensive care unit were each independently associated with death (after adjusting for covariates in the model); each increased the risk of dying by 7%–15%. Patients who required vasopressors had an absolute increase in risk for death of 50%, after covariates were adjusted for. Risk for death was independently associated with lower risk for death among those who had diabetes mellitus or who had had a vascular graft as the source of the infection. A consultation with an infectious diseases specialist decreased the risk for death by 11%. Neither a VISA nor hVISA strain was independently associated with all-cause death after covariates in the models were controlled for.

A subanalysis of vancomycin MICs for strains infecting patients who died in the hospital found that the mean MIC was 1.7 μg/mL. The current breakpoint of vancomycin susceptibility is 2 μg/mL.
Unlike others, who considered concurrent conditions by using scales such as the Charlson Index (15-24), we investigated the association between specific patient characteristics, organisms, drugs, and outcomes. Not all concurrent conditions were alike in either magnitude or direction of effect. Regression risk analysis enabled us to identify the independent contribution of these factors in relative and absolute terms. We identified critical prognostic factors, including concurrent conditions (cirrhosis and renal insufficiency suggested a poorer prognosis; diabetes, a better one) and source of admission (nursing home residence suggested a poorer prognosis). We learned that strain type was not an independent negative prognostic factor. As one might expect, the use of vasopressors presaged an increased risk for death (adjusted risk difference = 48%).

Our findings can help clinicians estimate the risk that a patient with MRSA bacteremia will die. For example, an elderly patient with liver cirrhosis and MRSA bacteremia who lived in a nursing home before hospital admission would have an extremely poor prognosis. Conversely, an otherwise healthy patient with diabetes mellitus might have a better prognosis that could be improved even more by consultation with an infectious disease specialist. We note paradoxically that several of the positive predictive factors (such as diabetes and vascular graft infections) represent situations in which host barriers to infections might be impaired. We speculate that host, organism, and drug factors might all interact; an impaired host might become infected by a less aggressive organism that in turn is more susceptible to drugs. In this study, ≈30% of patients with skin and soft tissue infections had diabetes mellitus with varying levels of baseline glucose control. Thus, the source of infection and spectrum of disease might also affect risk for death. This and alternate hypotheses should be explored in future research.

There is controversy regarding the value of testing for hVISA (25). Although this article is unlikely to resolve that controversy, we can say that patients infected with these strains in our cohort probably did not have increased risk for death from all causes. Other reports suggest that a down-regulation of virulence might be associated with increased vancomycin resistance (12,26).

We observed trends in which vancomycin MICs crept upward over the 5 years of the study. As a corollary, the likelihood of VISA infections increased. The rate of hVISA infections during 2002–2007 was steady, around 8%, similar to that described in the literature (27,28). Prior exposure to vancomycin was a contributing factor for infection with VISA strains (29–31). Although we describe a vancomycin MIC creep, the MIC90 of vancomycin remained relatively stable over the 5-year period, perhaps hinting at why MIC did not independently predict death.

A recent study by Paul et al. found a significant increase in 30-day mortality rates for patients given incorrect therapy within 48 hours of blood culture (32). Schweizer et al. did not find an increase in hospital deaths among similar patients with S. aureus bacteremia (33). Our study was limited by our inability to assess deaths that occurred out of the hospital.

Consistent with mortality rates reported in the literature, ≈32% of our patients died (34). Considering the marginal impact of several independent risk factors, our innovative presentation of adjusted risk differences offers clinicians a quantifiable way to assess their patients’ risk for death. Although the numbers were too low to analyze with multivariable models, we note the trend toward improved prognosis among those for whom antimicrobial drug therapy was switched and recognize that because switches are likely for patients who are not doing well clinically, that the most apparent bias is against such a finding. Thus, our findings hint at potential benefit for prescribing alternative drugs if patients are not improving. Two recent studies have shown that consultations with an infectious diseases specialist lower the risk for death from S. aureus bacteremia (35,36).

This study is limited by its retrospective design and single-center setting. MICs derived by using Etest might be higher than those derived by microdilution (37). hVISA strains were identified by using a method with demonstrably high sensitivity and specificity and not by using the standard method (10,38,39). We did not test for hVISA on the 5% of isolates for which vancomycin MIC
was <1 \mu g/mL; other studies have noted few or no hVISA in this MIC group (10, 24, 25, 27). The accuracy of timing of vancomycin trough levels was limited. Daily bacterial cultures were not always conducted, decreasing the data points for clearance of bacteremia. Misclassification error is possible because we reviewed records available at Mount Sinai Medical Center only. Almost all study patients had sufficient contact with the health care system that not many infections were classified as community acquired, limiting our ability to generalize to those infections. As noted, we were limited by our inability to link to death data outside of the hospital records.

Until now, the major focus on active MRSA infections has been on the organism and its susceptibility to the drug. Although decreased vancomycin susceptibility has resulted in prolonged bacteremia and treatment failure in several studies (15, 24), our findings suggest that incorporating the context, the host, and the environment is similarly useful. Our study emphasizes that after a diagnosis of MRSA bacteremia is made, it is crucial to determine patient risk factors and not just the vancomycin MIC for the infecting strain. The consequences of MRSA bacteremia are clear—many patients will die or experience a decline from their baseline clinical condition. The adjusted risk difference enables clinicians to use a targeted approach, directed toward patients with the highest risk for death—i.e., the elderly, patients with liver cirrhosis, patients with renal insufficiency, and patients from nursing homes. These patients should be treated carefully and should possibly receive a consult from an infectious diseases specialist. What remains unclear is whether patients with increased risk for death should be treated with antimicrobial drugs other than vancomycin.

### Table 3. Clinical characteristics for patients with MRSA bacteremia by strain type, New York, New York, USA, 2002–2007*

| Characteristic                                      | VISA, n = 55 | hVISA, n = 55 | non−VISA/hVISA MRSA, n = 589 | p value |
|-----------------------------------------------------|--------------|---------------|-----------------------------|---------|
| Age, mean y ± SD                                    | 58.7 ± 16.5  | 58.7 ± 16.5   | 63 ± 17.3                   | 0.04    |
| Length of stay, mean d ± SD                         | 33.7 ± 41.4  | 30.9 ± 22.7   | 34 ± 41.9                   | 0.49    |
| Days to negative culture, mean ± SD                | 3.7 ± 2.8    | 3.6 ± 3.2     | 4.3 ± 4.8                   | 0.98    |
| Male sex                                            | 29 (52.7)    | 28 (50.9)     | 340 (57.7)                  | 0.51    |
| Race/ethnicity                                      |              |               |                             |         |
| White                                               | 19 (34.5)    | 21 (38.2)     | 238 (40.4)                  | 0.59    |
| Black                                               | 15 (27.3)    | 14 (25.5)     | 160 (27.2)                  | 0.96    |
| Hispanic                                            | 12 (21.8)    | 7 (12.7)      | 123 (20.9)                  | 0.34    |
| Asian                                               | 9 (16.4)     | 10 (18.2)     | 65 (11.0)                   |         |
| General                                             |              |               |                             |         |
| Hospitalization within 1 mo of MRSA infection       | 29 (52.7)    | 17 (30.9)     | 295 (50.1)                  | 0.02    |
| Prior MRSA infection                                | 22 (40.0)    | 7 (12.7)      | 159 (27.0)                  | 0.006   |
| Prior vancomycin exposure                           | 34 (61.8)    | 25 (45.5)     | 272 (46.2)                  | 0.08    |
| Vancomycin trough >15 \mu g/mL                     | 34 (61.8)    | 25 (45.5)     | 387 (65.7)                  | 0.0005  |
| Inappropriate antimicrobial drug therapy             | 12 (21.8)    | 4 (7.3)       | 66 (11.2)                   | 0.09    |
| Infectious diseases consultation                    | 34 (61.8)    | 23 (41.8)     | 404 (68.6)                  | 0.0003  |
| Health care–associated hospital infection            | 19 (34.5)    | 28 (50.9)     | 340 (57.7)                  | 0.003   |
| Health care–associated community infection           | 31 (56.4)    | 25 (45.5)     | 241 (40.9)                  | 0.08    |
| Concurrent conditions                               |              |               |                             |         |
| Renal insufficiency                                 | 35 (63.6)    | 29 (52.7)     | 309 (52.5)                  | 0.48    |
| Chronic hemodialysis                                | 19 (34.5)    | 12 (21.8)     | 128 (21.7)                  | 0.09    |
| Diabetes mellitus                                   | 27 (49.1)    | 18 (32.7)     | 209 (35.5)                  | 0.11    |
| HIV                                                 | 5 (9.1)      | 2 (3.6)       | 60 (10.2)                   | 0.29    |
| Cardiovascular disease                              | 33 (60.0)    | 31 (56.4)     | 399 (67.7)                  | 0.14    |
| Malignancy                                          | 14 (25.5)    | 17 (30.9)     | 117 (19.9)                  | 0.11    |
| Transplant                                          | 7 (12.7)     | 11 (20.0)     | 46 (7.8)                    | 0.007   |
| Cirrhosis                                           | 22 (40.0)    | 14 (25.5)     | 78 (13.2)                   | <0.0001 |
| Steroids                                            | 17 (30.9)    | 12 (21.8)     | 193 (32.8)                  | 0.25    |
| Surgery <3 mo before MRSA infection                 | 14 (25.5)    | 19 (34.5)     | 271 (46.0)                  | 0.005   |
| Implanted device                                    | 8 (14.5)     | 7 (12.7)      | 151 (25.6)                  | 0.02    |
| Intensive care unit stay                            | 23 (41.8)    | 26 (47.3)     | 273 (46.3)                  | 0.96    |
| Infection source                                    |              |               |                             |         |
| Central venous catheter                             | 27 (49.1)    | 33 (60.0)     | 242 (41.1)                  | 0.04    |
| Pneumonia                                           | 10 (18.2)    | 6 (10.9)      | 39 (6.6)                    | 0.62    |
| Endocarditis                                        | 7 (12.7)     | 3 (5.5)       | 81 (13.8)                   | 0.22    |
| Wound/skin or soft tissue                           | 10 (18.2)    | 10 (18.2)     | 92 (15.6)                   | 0.60    |
| Bone/joint                                          | 6 (10.9)     | 1 (1.8)       | 65 (11.0)                   | 0.10    |
| Vascular graft                                      | 2 (3.6)      | 1 (1.8)       | 17 (2.9)                    | 0.85    |
| Death within 90 d of MRSA infection                 | 15 (27.3)    | 14 (25.5)     | 161 (27.3)                  | 0.38    |

*Values are no. (%) with a given variable per strain type unless otherwise indicated. MRSA, methicillin-resistant Staphylococcus aureus; VISA, vancomycin-intermediate S. aureus strains; hVISA, heteroresistant vancomycin-intermediate S. aureus strains.

TN = 699.
Acknowledgments

We thank Jeanette Francois for technical assistance with retesting strains.

This work was funded in part by a grant from Cubist Pharmaceuticals for reagent material and travel for presentations. S.G.J. executed the agreement, and M.P. was reimbursed for travel to the 19th European Congress of Clinical Microbiology and Infectious Diseases Meeting, Helsinki, Finland, and the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America Meeting, Washington, DC, to present part of the results.

The following isolates were obtained through the Network of Antimicrobial Resistance in Staphylococcus aureus program, supported under the National Institutes of Health/National Institute of Allergy and Infectious Diseases contract no. HHSN272200700055C: NRS 18, 19, 21, 22, 23, 24, 26, and 27.

Dr Pastagia is an instructor of clinical investigation in the Laboratory of Bacterial Pathology and Immunogenesis at The Rockefeller University. Her research focus is MRSA and novel treatment therapies.

References

1. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7:629–41. http://dx.doi.org/10.1038/nrmmicro2200
2. Finks J, Wells E, Dyke TL, Husain N, Plizga L, Heddurshetti R, et al. Vancomycin-resistant Staphylococcus aureus, Michigan, USA, 2007. Emerg Infect Dis. 2009;15:943–5. http://dx.doi.org/10.3201/eid1506.081312
3. Lalaní T, Boucher HW, Cosgrove SE, Fowler VG, Kanafani ZA, Vigliani GA, et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteremia. J Antimicrob Chemother. 2008;61:177–82. http://dx.doi.org/10.1093/jac/dkm437
4. Wunderink RG, Mendelson MH, Somero MS, Fabian TC, May AK, Bhattacharyya H, et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest. 2008;134:1200–7. http://dx.doi.org/10.1378/chest.08-0011
5. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207–8. http://dx.doi.org/10.1016/S0140-6736(01)05410-1
6. Mangili A, Bica I, Snyderman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40:1058–60. http://dx.doi.org/10.1086/428616
7. Steinbrügge G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother. 2007;60:788–94. http://dx.doi.org/10.1093/jac/dkm258
8. Wang G, Hinderer JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44:3883–6. http://dx.doi.org/10.1128/JCM.01388-06
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100–S16. Wayne (PA): The Institute; 2006.
10. Sakoulas G, Moise-Broder PA, Schentag JT, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398–402. http://dx.doi.org/10.1128/JCM.42.6.2398-2402.2004
11. Hidayaat LK, Hsi D, Quist R, Shiner KA, Wong-Berlinger A. High-dose vancomycin therapy for meticillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138–44. http://dx.doi.org/10.1001/archinte.166.19.2138
12. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193–200. http://dx.doi.org/10.1086/524667
13. Lodise TP, Graves J, Evans A, Graffunder E, Helmcke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52:3315–20. http://dx.doi.org/10.1128/AAC.00113-08
14. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448–51. http://dx.doi.org/10.1086/381093
15. Maor Y, Hagon M, Belauov N, Keller N, Ben-David D, Rahav G. Clinical features of heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis. 2009;199:619–24. http://dx.doi.org/10.1086/596629
16. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006;42(Suppl 1):S13–24. http://dx.doi.org/10.1086/491710
17. Velasco D, del Mar Tomas M, Cartelle M, Becerro A, Perez A, Molina F, et al. Evaluation of different methods for detecting methicillin (oxacillin) resistance in Staphylococcus aureus. J Antimicrob Chemother. 2005;55:379–82. http://dx.doi.org/10.1093/jac/dki017
18. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121–45. http://dx.doi.org/10.1177/096228029300200202
19. Klevens RM, Morrison MA, Nadle J, Pettit S, Gersham K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763–71. http://dx.doi.org/10.1001/jama.298.15.1763
20. Li JS, Sexton DJ, Mick N, Netles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633–8. http://dx.doi.org/10.1086/313753
21. SAS Institute. SAS 9.1 procedure user’s manual. Cary (NC): The Institute, Inc; 2004.
22. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373–9. http://dx.doi.org/10.1016/S0895-4356(96)00236-3
23. Kleinman LC, Norton EC. What’s the risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression. Health Serv Res. 2009;44:288–302. http://dx.doi.org/10.1111/j.1475-6773.2008.00900.x
24. Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol. 2009;47:1640–4. http://dx.doi.org/10.1128/JCM.02135-08

Risk for Death from MRSA Bacteremia
25. Horne KC, Howden BP, Grabsch EA, Graham M, Ward PB, Xie S, et al. Prospective comparison of the clinical impact of heterogeneous vancomycin-intermediate methicillin-resistant *Staphylococcus aureus* (hVISA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother. 2009;53:3447–52. http://dx.doi.org/10.1128/AAC.01365-08

26. Peleg AY, Monga D, Pillai S, Nylakonis E, Moellering RC Jr, Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in *Staphylococcus aureus* infection. J Infect Dis. 2009;199:532–6. http://dx.doi.org/10.1086/596511

27. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characterization of vancomycin-heteroresistant *Staphylococcus aureus* from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol. 2008;46:2950–4. http://dx.doi.org/10.1128/JCM.00582-08

28. Sun W, Chen H, Liu Y, Zhao C, Nichols WW, Chen M, et al. Prevalence and characterization of heterogeneous vancomycin-intermediate *Staphylococcus aureus* (hVISA) from 14 cities in China. Antimicrob Agents Chemother. 2009;53:3642–9. http://dx.doi.org/10.1128/AAC.00206-09

29. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, et al. Epidemiological and microbiological characterization of infections caused by *Staphylococcus aureus* with reduced susceptibility to vancomycin, United States, 1997–2001. Clin Infect Dis. 2003;36:429–39. http://dx.doi.org/10.1086/346207

30. Moise PA, Smyth DS, El-Fawal N, Robinson DA, Holden PN, Forrest A, et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant *Staphylococcus aureus* bacteraemia. J Antimicrob Chemother. 2008;61:85–90. http://dx.doi.org/10.1093/jac/dkm445

31. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, Richardson P, et al. Tracking the in vivo evolution of multidrug resistance in *Staphylococcus aureus* by whole-genome sequencing. Proc Natl Acad Sci U S A. 2007;104:9451–6. http://dx.doi.org/10.1073/pnas.0609839104

32. Paul M, Kariv G, Goldberg E, Raskin M, Shaked H, Hazan R, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant *Staphylococcus aureus* bacteraemia. J Antimicrob Chemother. 2010;65:2658–65. http://dx.doi.org/10.1093/jac/dkq373

33. Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shadell MD, McGregor JC, et al. Empiric antibiotic therapy for *Staphylococcus aureus* bacteremia may not reduce in-hospital mortality: a retrospective cohort study. PLoS ONE. 2010;5:e11432. http://dx.doi.org/10.1371/journal.pone.0011432

34. Kaye KS, Anderson DJ, Choi Y, Link K, Thacker P, Sexton DJ. The deadly toll of invasive methicillin-resistant *Staphylococcus aureus* infection in community hospitals. Clin Infect Dis. 2008;46:1568–77. http://dx.doi.org/10.1086/587673

35. Rieg S, Peyerl-Hoffmann G, de With K, Theilacker C, Wagner D, Hubner J, et al. Mortality of *S. aureus* bacteremia and infectious diseases specialist consultation—a study of 521 patients in Germany. J Infect. 2009;59:232–9. http://dx.doi.org/10.1016/j.jinf.2009.07.015

36. Laheyt T, Shah R, Gittus J, Schwartzman J, Kirkland K. Infectious diseases consultation lowers mortality from *Staphylococcus aureus* bacteremia. Medicine (Baltimore). 2009;88:263–7. http://dx.doi.org/10.1097/MD.0b013e3181b8fc6b

37. Sader HS, Rhomberg PR, Jones RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant *Staphylococcus aureus*. Antimicrob Agents Chemother. 2009;53:3162–5. http://dx.doi.org/10.1128/AAC.00093-09

38. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol. 2001;39:2439–44. http://dx.doi.org/10.1128/JCM.39.7.2439-2444.2001

39. Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating *Staphylococcus aureus* strains with reduced susceptibility to glycopeptides. J Clin Microbiol. 2007;45:329–32. http://dx.doi.org/10.1128/JCM.01508-06

Address for correspondence: Mina Pastagia, The Rockefeller University, 1230 York Ave, Bronk Building, 8th Floor, New York, NY 10065, USA; email: minapastagia@yahoo.com